🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06029660
Active, not recruiting Not applicable

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

NCT06029660 · tracked via the Priya Life Science UK tracker
Sponsor
Shape Memory Medical, Inc.
Phase
Not applicable
Started
2024-04-05
Last updated
2026-07-10

Condition(s) studied

Aortic Aneurysm, Abdominal

Investigational drug(s) / intervention(s)

IMPEDE-FX RapidFill ImplantsEndoVascular Aneurysm Repair

IMPEDE-FX RapidFill Implants: Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants

EndoVascular Aneurysm Repair: Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.

Study summary

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. ≥18 years of age 2. A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women; 3. Thrombus burden (percentage of the AAA sac occupied by thrombus) \<50%, based on pre-procedure CTA 4. Maximum Lumen diameter within the AAA sac of ≥40mm. 5. The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200. Exclusion Criteria: General 1. An inability to provide informed consent. 2. Enrolled in another clinical study that could interfere with the outcomes being studied in this trial. 3. Unable or unwilling to comply with study follow-up requirements. 4. Prisoner or member of other vulnerable population Anatomical 1. Concomitant iliac artery ectasia or aneurysm 2. Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac. 3. Ruptured, leaking, inflammatory or mycotic (infected) aneurysm. 4. Connective tissue disorder (e.g., Marfan's syndrome) 5. Aneurysmal disease of the descending thoracic aorta 6. Excessive calcification at the aortic bifurcation to common/internal iliac bifurcation, that might lead to access difficulties EVAR/Procedural 1. Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Gore Excluder Conformable AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II and Endurant IIs Stent Graft, or the Terumo TREO Stent Graft to treat the AAA 2. Use of an aortic stent graft other than those specified1 for a particular site 3. Planned use of the chosen stent graft outside its instructions for use (IFU) 4. Use of fenestrated stent grafts or chimney techniques 5. Use of the Heli-FX EndoAnchor system 6. Use of embolic devices other than the investigational product to embolize the AAA sac 7. Use of embolic products to prophylactically or concomitantly embolize the inferior mesenteric artery, lumbar arteries, renal accessory arteries, or internal iliac arteries 8. Inability to land the distal-most portion of the EVAR stent graft limbs, including extensions, above the internal iliac arteries Medical History/Conditions 1. Coagulopathy or uncontrolled bleeding disorder 2. Serum creatinine level \>2.5 mg/dL 3. Cerebrovascular accident within 3 months prior to the procedure 4. Myocardial infarction and/or major heart surgery within 3 months prior to the procedure 5. Atrial fibrillation that is not well rate controlled 6. Life expectancy of \<2 years post-procedure 7. Known hypersensitivity or contraindication to platinum, iridium, or polyurethane. 8. Have active infection at the time of the index procedure documented by pain, fever, drainage, positive culture, or leukocytosis (WBC \>11,000/mm3) 9. A condition that inhibits radiographic visualization during the implantation procedure 10. History of allergy to contrast medium that cannot be managed medically, or subject is unable to have a CT with contrast for any reason. 11. Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the trial 12. Pregnant or lactating female: for females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the trial

Primary outcome measure(s)

Trial sites (49)

FacilityCityRegionStatus
University of Alabama Birmingham Birmingham Alabama
Honor Health Scottsdale Arizona
USC Keck Los Angeles California
San Diego VA Medical Center San Diego California
Delray Medical Center Delray Beach Florida
Mt. Sinai Medical Center Miami Beach Florida
Orlando Health Orlando Florida
University of South Florida Tampa Florida
Emory University Hospital Atlanta Georgia
University of Chicago Chicago Illinois
Indiana University Indianapolis Indiana
Maine Medical Portland Maine
Johns Hopkins Baltimore Maryland
Massachusetts General Hospital Boston Massachusetts
Brigham & Women's Hospital Boston Massachusetts
Beth Israel Deaconess Medical Center Boston Massachusetts
VA Ann Arbor Healthcare Ann Arbor Michigan
Corewell Health Grand Rapids Michigan
Mayo Clinic Rochester Minnesota
Dartmouth Hitchcock Medical Center Lebanon New Hampshire
University at Buffalo Buffalo New York
Buffalo VA Western New York Buffalo New York
NYU Langone New York New York
Columbia University Irving Medical Center/New York Presbyterian Hospital New York New York
University of Rochester Rochester New York
Stony Brook Medicine Stony Brook New York
TriHealth Heart Institute Cincinnati Ohio
Ohio State University Wexner Medical Center Columbus Ohio
The Hospital of the University of Pennsylvania Philadelphia Pennsylvania
Sanford Health Sioux Falls South Dakota
Vanderbilt University Nashville Tennessee
St. David's Healthcare Austin Texas
Houston Methodist Houston Texas
Baylor Scott and White Plano Texas
The University of Texas Health Science Center at San Antonio San Antonio Texas
University of Virginia Charlottesville Virginia
Inova Schar Heart and Vascular Falls Church Virginia
Sentara Norfolk General Norfolk Virginia
University of Wisconsin Madison Wisconsin
Hopital Cardiologie Lille Hauts-de-France

+ 9 more sites — see the full list on the official registry below.

More Shape Memory Medical, Inc. trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06029660 on ClinicalTrials.gov ↗ ← All trials in the UK